Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
about
Development of targeted therapies in treatment of glioblastomaNFAT1 is highly expressed in, and regulates the invasion of, glioblastoma multiforme cellsUpregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma.New approach to develop ultra-high inhibitory drug using the power function of the stoichiometry of the targeted nanomachine or biocomplex.Small molecules targeting microRNA for cancer therapy: Promises and obstacles.Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).A mechanism for the upregulation of EGF receptor levels in glioblastomasSignal Transducer and Activator of Transcription 3/MicroRNA-21 Feedback Loop Contributes to Atrial Fibrillation by Promoting Atrial Fibrosis in a Rat Sterile Pericarditis ModelSequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier.MicroRNA-21: a therapeutic target for reversing drug resistance in cancer.Emerging roles of microRNA in modulating cell-death processes in malignant glioma.Interplay between microRNAs and the STAT3 signaling pathway in human cancers.Discovery of a new method for potent drug development using power function of stoichiometry of homomeric biocomplexes or biological nanomotorsCo-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells.Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221.miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment.MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions.Rod-Shaped Active Drug Particles Enable Efficient and Safe Gene Delivery.Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells.The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes.Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model.Dendrimers Show Promise for siRNA and microRNA Therapeutics
P2860
Q26778787-B9FEFB66-EC0F-4FFF-9B46-2DB3F39C8058Q34770388-41EDFAAA-3D19-49ED-B71C-4A48DA661F3EQ35964266-C946E879-7C5F-4453-AF86-62D569296057Q36522581-A6ADE83E-9A37-40A6-B13B-F477F1E13CFBQ36567511-8AE87A39-7DFA-4B89-96FF-FB855BE10284Q36992190-944935E3-CD21-4276-B93A-D47151835879Q37091283-193A6404-F953-488F-BB0D-9407AC0A6842Q37116392-062FDC25-DF5D-40C1-B143-1D1BE52F602FQ37696302-3356E518-C6B8-4CA9-9EA3-276E9E728743Q38122420-8B18468E-D0C3-4B2C-AB81-8F0C885207F4Q38127635-02E2D9E1-56DC-40F0-BC80-FBC251F170D2Q38160108-CA7CB52A-FADC-42D6-A5B4-90AAA6447657Q38573837-B2F9DC29-F280-4C86-AA88-16D94B9EC7D8Q38765826-2C38A823-03AE-4D6E-BBED-0787793A96DEQ38787321-84D005A5-3E9F-4CF6-9E0B-54439D4F1CC6Q38836010-CA5EF897-CC9E-4221-9791-4034B5F58020Q39018554-3B8AE042-27E3-4A37-8F01-AF55A9E0A716Q39020586-08B68FC7-EB76-471A-8B20-84072D9C57A5Q39228006-5F55DCF7-41DE-4C2E-BE15-C3449CE7BC45Q41459815-5FA1523D-9D8C-4810-875D-D25BC422241FQ41721647-79CABCE9-FE97-4732-AFBE-B62BE8AB098CQ45875385-3E6C7A91-860F-431C-A29C-710664C2249FQ47138564-BA173E82-27DF-4608-A955-23C7497D5347Q47403872-A6483098-0FD3-4C9B-B639-290740EF9090Q50098046-55BB4B5C-8238-4D46-91E1-8F725BBAFE3AQ51416808-94FE20AE-B2EE-4431-B4DB-AAE44FC1FE1EQ55257510-64EDB2CF-8E0E-4708-927A-C436E0D0907EQ58794827-D55EC509-DE4D-4E6C-BA84-C9BFB7CD154A
P2860
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@en
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@nl
type
label
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@en
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@nl
prefLabel
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@en
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@nl
P2093
P356
P1476
Sequence-dependent synergistic ...... miR-21 inhibitor gene therapy.
@en
P2093
Chunsheng Kang
Jing Sheng
Lixia Long
Xiaomin Qian
Zhendong Shi
P304
P356
10.1021/MP3002039
P407
P577
2012-08-23T00:00:00Z